Compare CubeSmart (CUBE) vs Smith & Nephew plc (SNN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
CubeSmart vs Smith & Nephew plc — how do they compare? CubeSmart trades at $37.56 (market cap $8.45B), while Smith & Nephew plc trades at $27.22 (market cap $11.10B). The key difference: Smith & Nephew plc is the larger of the two by market cap, and CubeSmart pays the higher dividend (5.65%). Which is the better fit depends on your goals — on Pluang, investors hold CubeSmart for 89 Days and Smith & Nephew plc for 120 Days on average.
| CUBE | SNN | |
|---|---|---|
Market Cap | $8.45B | $11.10B |
Volume | 2,879,532 | 1,051,703 |
Sector | Real Estate | Health |
52-Week High | $42.50 | $37.17 |
52-Week Low | $35.36 | $26.42 |
Typical Hold Time | 89 Days | 120 Days |
Enterprise Value | $11.97B | $14.13B |
Dividend Yield | 5.65% | 2.95% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CubeSmart (CUBE) trades at $37.23, down 1.4% on the day, amid a bearish technical signal from moving averages. The self-storage REIT reported mixed Q2 2026 results with an FFO miss but revenue beat, and same-store NOI declined 0.7%. Financials show strong gross margins of 67.83% and net income margin of 29.41%, though net income has trended down from $411M in 2023 to $334M in 2025. Analyst consensus is a Buy with a $44.00 price target, implying 18% upside, but technical indicators suggest near-term resistance at $38.
CUBE offers a 5.4% dividend yield with a payout scheduled for October 2026, supporting income-focused investors. Upside is driven by moderating supply and strengthening demand in the self-storage sector, but risks include high leverage with $2.99B long-term debt and macroeconomic sensitivity. Institutional activity is mixed, with new positions from Deutsche Bank and Barrow Hanley offset by selling from HSBC. The stock presents a value opportunity if operational improvements materialize, though debt levels and same-store performance warrant caution.
Smith & Nephew (SNN) trades at $26.89, near its 52-week low, with a bearish technical signal. Revenue grew to $6.16B in 2025, with net income margin improving to 10.08%. Recent product launches, like the EVOS PELVIC System, aim to strengthen its medical technology portfolio, though the stock faces headwinds from analyst downgrades and CFO departure news.
The outlook is cautious; while fundamentals show profitability growth, the stock's proximity to lows and mixed analyst sentiment (26% buy, 65% hold) suggest limited near-term upside. Key risks include competitive pressures and execution challenges, but the stable dividend and institutional interest offer some support for patient investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About CubeSmart
CubeSmart is a real estate investment trust that acquires, owns, and manages self-storage facilities throughout the United States. The company's real estate portfolio is composed of buildings with numerous enclosed storage areas for both residential and commercial customers to rent mainly on a month-by-month basis. Most of CubeSmart's facilities are located in Florida, Texas, California, New York, and Illinois. Cumulatively, these states account for both the majority of the square footage in the company's real estate portfolio and the majority of its revenue. CubeSmart derives nearly all of its revenue from rental income from tenants utilizing its storage facilities.
Read more on CUBE →About Smith & Nephew plc
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
Read more on SNN →
